Full transparency of ticagrelor trials in coronary artery disease should be warranted.

Ennezat, Pierre-Vladimir; Guerbaai, Raphaëlle-Ashley; LeJemtel, Thierry H; Hansen, Morten Rix

Ennezat, Pierre-Vladimir; Guerbaai, Raphaëlle-Ashley; LeJemtel, Thierry H; Hansen, Morten Rix.

Affiliation

Ennezat PV; Cardiology department, Service de cardiologie, Centre Hospitalier Universitaire Henri Mondor, Créteil, France.
Guerbaai RA; Medizinische Fakultät, Department Public Health (DPH), Universität Basel, Basel, Switzerland.
LeJemtel TH; University Heart and Vascular Institute, New Orleans, LA, USA.
Hansen MR; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Hosp Pract (1995) ; 50(2): 89-92, 2022 04.

Article in En | MEDLINE | ID: mdl-35236204

Subject(s)

Acute Coronary Syndrome; Coronary Artery Disease; Percutaneous Coronary Intervention; Coronary Artery Disease/drug therapy; Humans; Platelet Aggregation Inhibitors/therapeutic use; Purinergic P2Y Receptor Antagonists/therapeutic use; Ticagrelor/therapeutic use; Treatment Outcome

Key words

Ticagrelor; clopidogrel; randomized controlled trial; transparency

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Acute Coronary Syndrome / Percutaneous Coronary Intervention Limits: Humans Language: En Journal: Hosp Pract (1995) Journal subject: HOSPITAIS Year: 2022 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google